A xenograft tumor assay demonstrated that breast cancer cells that overexpress CNNM3 are more oncogenic compared with CNNM3 G433D, a mutant without ability to bind to PRL-2 (Hardy et al., 2015; Kostantin et al., 2016). This evidence concerns the gene PTP4A2 and breast cancer.